Indometacin farnesil
From Self-sufficiency
| File:Infree.png | |
| Systematic (IUPAC) name | |
|---|---|
|
(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetate | |
| Clinical data | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | To indometacin |
| Biological half-life | 1.5 hours |
| Excretion | Renal |
| Identifiers | |
| CAS Number | 85801-02-1 |
| PubChem | CID 5282183 |
| Chemical data | |
| Formula | C34H40ClNO4 |
| Molar mass | 562.14 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Indometacin farnesil (INN) is a prodrug of the non-steroidal anti-inflammatory drug indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon respectively.
External links
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Articles containing unverified chemical infoboxes
- 2Fix
- Non-steroidal anti-inflammatory drugs
- Indoles
- Prodrugs
- Sesquiterpenes
- Pharmacology stubs
